ORLANDO — A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in age-related macular degeneration assessment, according to a speaker here.
At the American Academy of Ophthalmology meeting, Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates, presented results from the OCT Fx Delphi study, which aimed to “establish global consensus on the role of the ellipsoid zone (EZ) as a clinically relevant endpoint connecting structure and function in AMD trials,” he told Healio.
{{VIDEO}}
According to Khanani, EZ loss and EZ retinal